Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

ImmunoCellular Therapeutics updates on phase II ICT-107 trial

Sep. 8, 2011

MorphoSys initiates dosing in MOR-202 multiple myeloma trial

Sep. 1, 2011

New cDNA library vaccine cures experimental prostate cancer

Aug. 25, 2011

FDA sets PDUFA date for Amgen's sBLA for Xgeva

Aug. 24, 2011

Phase II trial of Adcetris in CD30-positive non-Hodgkin's lymphoma begins

Aug. 24, 2011

Monoclonal antibody recognizes human embryonic stem cells with teratoma-forming potential

Aug. 24, 2011

Symphogen begins phase II trial of Sym-004 in head and neck cancer

Aug. 23, 2011

First patient enrolled in phase I/II study of Hemispherx's Ampligen in breast cancer

Aug. 23, 2011

Mayo Clinic obtains IND clearance for ovarian and breast cancer vaccine trials

Aug. 23, 2011

FDA grants accelerated approval to Adcetris for two indications

Aug. 22, 2011

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...